Brian J. Lannutti

6.1k citations

75 papers · 4.0k indexed · 3 hit papers · h-index 29

Genetics top 0.2%
Molecular Biology top 5%
Pathology and Forensic Medicine top 0.5%
Immunology top 2%
Hematology top 1%

Co-authors: Neill A. Giese Sarah Meadows John C. Byrd Roger G. Ulrich Langdon L. Miller Kamal D. Puri Amy J. Johnson Albert S. Yu
Topics: Chronic Lymphocytic Leukemia Research (48 papers)PI3K/AKT/mTOR signaling in cancer (26 papers)Lymphoma Diagnosis and Treatment (19 papers)
Cited by: Genetics Pathology and Forensic Medicine Hematology
Journals: Journal of Biological Chemistry Journal of Clinical Oncology Blood
Partner nations: United States Italy Denmark

In The Last Decade

Brian J. Lannutti

74 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

2010 588 citations Brian J. Lannutti, Sarah Meadows et al. Blood profile →
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

2014 465 citations Stephen E. Spurgeon, Brian J. Lannutti et al. Blood profile →
The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

2011 442 citations Julia Hoellenriegel, Sarah Meadows et al. Blood profile →

Peers

Countries citing papers authored by Brian J. Lannutti

Since Specialization

Citations

This map shows the geographic impact of Brian J. Lannutti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian J. Lannutti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian J. Lannutti more than expected).

Fields of papers citing papers by Brian J. Lannutti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian J. Lannutti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian J. Lannutti. The network helps show where Brian J. Lannutti may publish in the future.

Co-authorship network of co-authors of Brian J. Lannutti

This figure shows the co-authorship network connecting the top 25 collaborators of Brian J. Lannutti. A scholar is included among the top collaborators of Brian J. Lannutti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian J. Lannutti. Brian J. Lannutti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model 2017 ·Clinical Cancer Research ·Carsten Utoft Niemann,Helena Mora-Jensen,Eman L. Dadashian,Fanny Krantz,Todd Covey,Shih‐Shih Chen,Nicholas Chiorazzi,Raquel Izumi,Roger G. Ulrich,Brian J. Lannutti,Adrian Wiestner,Sarah E. M. Herman	25
2	PI3Kγ/δ and NOTCH1 Cross-Regulate Pathways That Define the T-cell Acute Lymphoblastic Leukemia Disease Signature 2017 ·Molecular Cancer Therapeutics ·(unknown),Utpal P. Davé,Irina V. Lebedeva,Yao Shen,Maria J. Sanchez‐Quintero,Daniel Diolaiti,Andrew L. Kung,Brian J. Lannutti,(unknown),Ronald Realubit,Zoya Niatsetskaya,Vadim S. Ten,Charles Karan,Xi Chen,Andrea Califano,Thomas G. Diacovo	7
3	A phase I, first-in-human, dose escalation study of intravenous TK216 in patients with relapsed or refractory Ewing sarcoma. 2017 ·Journal of Clinical Oncology ·Noah Federman,Paul A. Meyers,Najat C. Daw,Jeffrey A. Toretsky,James B. Breitmeyer,Arun S. Singh,Langdon L. Miller,Tilman Oltersdorf,(unknown),Katayoun A. Jessen,Brian J. Lannutti,Joseph A. Ludwig	4
4	The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia 2016 ·Clinical Cancer Research ·Sarah E. M. Herman,Arnau Montraveta,Carsten Utoft Niemann,Helena Mora-Jensen,Michael Gulrajani,Fanny Krantz,Rose Mantel,Lisa L. Smith,Fabienne McClanahan,Bonnie K. Harrington,Dolors Colomer,Todd Covey,John C. Byrd,Raquel Izumi,Allard Kaptein,Roger G. Ulrich,Amy J. Johnson,Brian J. Lannutti,Adrian Wiestner,Jennifer A. Woyach	121
5	Abstract 4797: The combination of ACP-196 and ACP-319 leads to increased survival in the TCL1-192 CLL mouse model 2016 ·Cancer Research ·Helena Mora-Jensen,Carsten Utoft Niemann,Michael Gulrajani,Fanny Krantz,Todd Covey,Brian J. Lannutti,Adrian Wiestner,Sarah E. M. Herman	1
6	Effects of Isoform-selective Phosphatidylinositol 3-Kinase Inhibitors on Osteoclasts 2013 ·Journal of Biological Chemistry ·(unknown),(unknown),Natsuko Tanabe,Adam Kashishian,Bart Steiner,Kamal D. Puri,Alexey Pereverzev,Brian J. Lannutti,Frank R. Jirik,S. Jeffrey Dixon,Stephen M. Sims	36
7	The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells 2013 ·PLoS ONE ·Stefania Fiorcari,Wells S. Brown,Bradley W. McIntyre,Zeev Estrov,Rossana Maffei,Susan O’Brien,Mariela Sivina,Julia Hoellenriegel,William G. Wierda,Michael J. Keating,Wei Ding,Neil E. Kay,Brian J. Lannutti,Roberto Marasca,Jan A. Burger	75
8	Induction of prolonged early G₁arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1 2013 ·Cell Cycle ·David Chiron,Peter Martin,Maurizio Di Liberto,Xiangao Huang,Scott Ely,Brian J. Lannutti,John P. Leonard,Christopher E. Mason,Selina Chen‐Kiang	59
9	Specific inhibition of PI3K p110δ inhibits CSF‐1‐induced macrophage spreading and invasive capacity 2013 ·FEBS Journal ·Kellie A. Mouchemore,Natália G. Sampaio,(unknown),E. Richard Stanley,Brian J. Lannutti,Fiona J. Pixley	30
10	A Potential Therapeutic Strategy for Chronic Lymphocytic Leukemia by Combining GS-1101, a PI3 kinase Delta (PI3Kδ) Inhibitor and a Novel Highly Selective Spleen Tyrosine Kinase (Syk) Inhibitor, GS-9973 2012 ·Blood ·Russell T. Burke,Astrid Clarke,Sarah Meadows,Marc Loriaux,(unknown),Guang Fan,Patrícia Maciejewski,Julie Di Paolo,Brian J. Lannutti,Brian Druker,Stephen E. Spurgeon	2
11	Targeting Nonclassical Oncogenes for Therapy in T-ALL 2012 ·Cancer Cell ·Prem S. Subramaniam,(unknown),(unknown),(unknown),Valeria Tosello,Kim De Keersmaecker,Adam Kashishian,Mary Ann Thompson,Mireia Castillo-Martín,Carlos Cordon‐Cardo,Utpal P. Davé,Adolfo A. Ferrando,Brian J. Lannutti,Thomas G. Diacovo	69
12	The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemiabreakdown → 2011 ·Blood ·Julia Hoellenriegel,Sarah Meadows,Mariela Sivina,William G. Wierda,Hagop M. Kantarjian,Michael J. Keating,Neill A. Giese,Susan O’Brien,Albert S. Yu,Langdon L. Miller,Brian J. Lannutti,Jan A. Burger	442
13	PI3K/p110δ is a novel therapeutic target in multiple myeloma 2010 ·Blood ·Hiroshi Ikeda,Teru Hideshima,Mariateresa Fulciniti,Giulia Perrone,Naoya Miura,Hiroshi Yasui,Yutaka Okawa,Tanyel Kiziltepe,Loredana Santo,Sonia Vallet,(unknown),Elisabetta Calabrese,Güllü Görgün,Noopur Raje,Paul G. Richardson,Nikhil C. Munshi,Brian J. Lannutti,Kamal D. Puri,Neill A. Giese,Kenneth C. Anderson	156
14	Expression of the GPI-anchored receptor Prv-1 enhances thrombopoietin and IL-3-induced proliferation in hematopoietic cell lines 2007 ·Leukemia Research ·(unknown),(unknown),(unknown),Brian J. Lannutti	5
15	Increased megakaryocytopoiesis in Lyn-deficient mice 2006 ·Oncogene ·Brian J. Lannutti,(unknown),(unknown),Jonathan G. Drachman	38
16	A novel strategy for generating platelet-like fragments from megakaryocytic cell lines and human progenitor cells 2005 ·Blood Cells Molecules and Diseases ·Manish J. Gandhi,Jonathan G. Drachman,Jo-Anna Reems,David Thorning,Brian J. Lannutti	22
17	Identification and activation of Src family kinases in primary megakaryocytes 2003 ·Experimental Hematology ·Brian J. Lannutti,(unknown),(unknown),Jo Anna Reems,Jonathan G. Drachman	38
18	Gprk2 Controls cAMP Levels in Drosophila Development 2001 ·Developmental Biology ·Brian J. Lannutti,(unknown)	17
19	In Vivo Gene Therapy with Interleukin-12 Inhibits Primary Vascular Tumor Growth and Induces Apoptosis in a Mouse Model1 1999 ·Journal of Investigative Dermatology ·Chong Wang,(unknown),Brian J. Lannutti,Kenneth B. Gordon,Dan‐qing Guo,W H Sun,Amy S. Paller	31
20	Integrin α5β1 Expression Is Required for Inhibition of Keratinocyte Migration by Ganglioside GT1b 1998 ·Experimental Cell Research ·(unknown),Edel A. O’Toole,Brian J. Lannutti,(unknown),Maurice R.G. O’Gorman,David T. Woodley,Amy S. Paller	24

About Brian J. Lannutti

Brian J. Lannutti is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine, having authored 75 papers that have together received 4.0k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (48 papers), PI3K/AKT/mTOR signaling in cancer (26 papers) and Lymphoma Diagnosis and Treatment (19 papers). The work is most often cited by research in Genetics (2.6k citations), Pathology and Forensic Medicine (1.7k citations) and Hematology (991 citations). Brian J. Lannutti has collaborated with scholars based in United States, Italy and Denmark. Frequent co-authors include Neill A. Giese, Sarah Meadows, John C. Byrd, Roger G. Ulrich, Langdon L. Miller, Kamal D. Puri, Amy J. Johnson, Albert S. Yu, Sarah E.M. Herman and Adam Kashishian. Their work appears in journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact